Supplementary Figure 2 from Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non–Small Cell Lung Cancer

MLA

Ravi Salgia, et al. Supplementary Figure 2 from Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non–Small Cell Lung Cancer. Mar. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....3a72ddd7a9140862a9c2b3cd03c00dec&authtype=sso&custid=ns315887.

APA

Ravi Salgia, Everett E. Vokes, Aliya N. Husain, Erin Smithberger, Jeffrey Mueller, Qudsia Arif, Rifat Hasina, & Ichiro Kawada. (2023). Supplementary Figure 2 from Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non–Small Cell Lung Cancer.

Chicago

Ravi Salgia, Everett E. Vokes, Aliya N. Husain, Erin Smithberger, Jeffrey Mueller, Qudsia Arif, Rifat Hasina, and Ichiro Kawada. 2023. “Supplementary Figure 2 from Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non–Small Cell Lung Cancer,” March. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....3a72ddd7a9140862a9c2b3cd03c00dec&authtype=sso&custid=ns315887.